Chemotherapy News and Research

Latest Chemotherapy News and Research

Hyperbaric oxygen therapy improves outcomes of umbilical cord blood transplant patients

For the past 27 years, cord blood transplants have been a life-saving treatment option for thousands of people with leukemia, non-Hodgkins lymphoma, Hodgkins disease and myelodysplastic disorders. Cord blood helps replace cancerous blood cells and replenish a patient's own bone marrow and immune system. Even with its success, researchers are continually looking for ways to improve the transplant process and increase cure rates.

24 Sep 2015

Discovery opens door to more targeted, effective treatments for cancer

In a discovery that could lead to more targeted and effective treatments for certain lung and prostate cancers, researchers at the University of Virginia School of Medicine have identified two new cancer-causing gene mutations - mutations that may be particularly susceptible to cancer-fighting drugs already approved by the federal Food and Drug Administration. One of the gene mutations also may play a key role in early menopause.

24 Sep 2015

Stanford researchers successfully defeat C. difficile bacteria

Stanford University School of Medicine scientists successfully defeated a dangerous intestinal pathogen, Clostridium difficile, with a drug targeting its toxins rather than its life.

24 Sep 2015

TUM, Stanford University scientists create new cancer therapy concept

Pancreatic cancer is one of the most aggressive forms of cancer and one of the most difficult to treat. Its high resistance to treatment is a major problem, particularly in the advanced stages.

24 Sep 2015

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.

23 Sep 2015

Johns Hopkins scientists discover earliest premalignant genetic changes that mark potential onset of lung cancer

Working with tissue, blood and DNA from six people with precancerous and cancerous lung lesions, a team of Johns Hopkins scientists has identified what it believes are among the very earliest “premalignant” genetic changes that mark the potential onset of the most common and deadliest form of disease.

23 Sep 2015

Paxman unveils commitment to ‘chase zero hair loss during chemotherapy’ at 2015 European Cancer Congress

UK based Paxman – pioneers in scalp cooling – is unveiling their commitment to ‘chase zero hair loss during chemotherapy’ at the 2015 European Cancer Congress, Europe’s largest cancer platform being held in Vienna, Austria (September 25 – 29th, 2015).

From Paxman 23 Sep 2015

Drug combination delivers effective punch against one form of pancreatic cancer

One form of pancreatic cancer has a new enemy: a two-drug combination discovered by UF Health researchers that inhibits tumors and kills cancer cells in mouse models.

22 Sep 2015

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

22 Sep 2015

Caring for women who develop invasive breast tumor in Germany

Every year, more than 70 000 women in Germany develop an invasive breast tumor. This makes breast cancer the most common tumor disease in women. The current edition of Deutsches Ärzteblatt International (Edition 35/36) contains no less than three articles focusing on breast cancer.

22 Sep 2015

Innovative way may stop spread of glioblastoma multiforme

Scientists at the University of Toledo Health Science Campus and Van Andel Research Institute have discovered an innovative way that may stop the spread of the most lethal and aggressive brain cancer glioblastoma multiforme (GBM). In laboratory studies, scientists demonstrated that activating a specific family of proteins halted cancer cell migration into healthy tissue.

22 Sep 2015

T2 Biosystems' T2Candida Panel more sensitive than blood culture for monitoring patients on antifungal therapy

T2 Biosystems, Inc. a company developing innovative diagnostic products to improve patient health, today announced that data on its T2Candida Panel was presented today at the Interscience Conference on Antimicrobial Agents and Chemotherapy and the International Society of Chemotherapy joint meeting in San Diego, CA.

22 Sep 2015

AmpliPhi's novel bacteriophage therapy demonstrates comparable efficacy to vancomycin in S. aureus lung infection model

AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced experimental results highlighting that its prototype bacteriophage cocktail demonstrated comparable efficacy to vancomycin in reduction of Staphylococcus aureus in a murine lung infection model.

22 Sep 2015

Researchers identify a protein that could potentially stop cancer

Scientists know that most cancer cells use glucose to fuel their uncontrolled growth and now an international team of researchers has identified a protein which if switched off could stop the disease in its tracks.

22 Sep 2015

Bretuximab vedotin safe, effective for older Hodgkin lymphoma patients unfit for chemotherapy

A study, published online in Blood, the Journal of the American Society of Hematology, reports that bretuximab vedotin is an effective and safe first course of treatment for older Hodgkin lymphoma patients unfit for chemotherapy.

22 Sep 2015

Outbreak of Bordetella parapertussis occurred in Southeastern Minnesota in 2014: Study

Study reports that an outbreak of Bordetella parapertussis occurred in 2014 in Southeastern Minnesota, in the months of October through December. This research is presented at ASM's 55th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC/ICC).

22 Sep 2015

New study calls for new treatments for carbapenem-resistant Enterobacteriaceae infection

Researchers at The Medicines Company presented data from a multi-national cohort that demonstrates the mortality and morbidity, and poor outcomes, associated with current therapies in patients with infections due to carbapenem-resistant Enterobacteriaceae (CRE). The data from this analysis has guided the design of the company’s on-going clinical studies of its Phase 3 compound, CARBAVANCE® (meropenem/RPX7009) and was presented at the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy and Infection (ICC) joint meeting in San Diego, CA.

22 Sep 2015

Pneumococcal and rotavirus vaccines lead to rapid reduction in pediatric hospital burden

Researchers show that the introduction of both pneumococcal conjugate vaccines (PCVs) and rotavirus vaccines (RVs) led to the rapid and dramatic reduction in hospital burden of both winter diarrhea and respiratory infections within <5 years post introduction of the vaccines.

22 Sep 2015

Study compares effectiveness of nafcillin and cefazolin in patients with MSSA blood stream infections

Research comparing clinical outcomes between patients receiving nafcillin and cefazolin for treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia shows that overall treatment failure rate among patients receiving cefazolin was no worse than nafcillin, and significantly fewer adverse effects were documented for those receiving cefazolin.

22 Sep 2015

Arsenic trioxide feasible in low-, high-risk acute promyelocytic leukaemia

The use of arsenic trioxide instead of idarubicin in combination with all-trans retinoic acid is a feasible option in patients with acute promyelocytic leukaemia, regardless of risk level, suggests a phase III trial.

21 Sep 2015

Chemotherapy News and Research

Latest Chemotherapy News and Research

Hyperbaric oxygen therapy improves outcomes of umbilical cord blood transplant patients

Discovery opens door to more targeted, effective treatments for cancer

Stanford researchers successfully defeat C. difficile bacteria

TUM, Stanford University scientists create new cancer therapy concept

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

Johns Hopkins scientists discover earliest premalignant genetic changes that mark potential onset of lung cancer

Paxman unveils commitment to ‘chase zero hair loss during chemotherapy’ at 2015 European Cancer Congress

Drug combination delivers effective punch against one form of pancreatic cancer

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Caring for women who develop invasive breast tumor in Germany

Innovative way may stop spread of glioblastoma multiforme

T2 Biosystems' T2Candida Panel more sensitive than blood culture for monitoring patients on antifungal therapy

AmpliPhi's novel bacteriophage therapy demonstrates comparable efficacy to vancomycin in S. aureus lung infection model

Researchers identify a protein that could potentially stop cancer

Bretuximab vedotin safe, effective for older Hodgkin lymphoma patients unfit for chemotherapy

Outbreak of Bordetella parapertussis occurred in Southeastern Minnesota in 2014: Study

New study calls for new treatments for carbapenem-resistant Enterobacteriaceae infection

Pneumococcal and rotavirus vaccines lead to rapid reduction in pediatric hospital burden

Study compares effectiveness of nafcillin and cefazolin in patients with MSSA blood stream infections

Arsenic trioxide feasible in low-, high-risk acute promyelocytic leukaemia

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in